These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35272914)

  • 21. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study.
    Vedovati MC; Mosconi MG; Isidori F; Agnelli G; Becattini C
    J Thromb Thrombolysis; 2020 Feb; 49(2):251-258. PubMed ID: 31520364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytosorb
    Mendes V; Colombier S; Verdy F; Bechtold X; Schlaepfer P; Scala E; Schneider A; Kirsch M
    Perfusion; 2021 Nov; 36(8):873-875. PubMed ID: 33106093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme.
    Tripodi A; Chantarangkul V; Legnani C; Testa S; Tosetto A
    J Thromb Haemost; 2018 Mar; 16(3):565-570. PubMed ID: 29322630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
    Schmitz EM; Boonen K; van den Heuvel DJ; van Dongen JL; Schellings MW; Emmen JM; van der Graaf F; Brunsveld L; van de Kerkhof D
    J Thromb Haemost; 2014 Oct; 12(10):1636-46. PubMed ID: 25142183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
    Wong PC; White A; Luettgen J
    Hosp Pract (1995); 2013 Feb; 41(1):19-25. PubMed ID: 23466964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
    Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
    Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.
    Du S; Harenberg J; Krämer S; Krämer R; Wehling M; Weiss C
    Ther Drug Monit; 2015 Jun; 37(3):375-80. PubMed ID: 25525760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Influence of NOACs on Thrombin Generation Assay].
    Kawasugi K
    Rinsho Byori; 2014 Oct; 62(10):965-9. PubMed ID: 27526542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
    Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
    Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban.
    Platton S; Hunt C
    Int J Lab Hematol; 2019 Apr; 41(2):227-233. PubMed ID: 30468572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multimodal assessment of non-specific hemostatic agents for apixaban reversal.
    Martin AC; Gouin-Thibault I; Siguret V; Mordohay A; Samama CM; Gaussem P; Le Bonniec B; Godier A
    J Thromb Haemost; 2015 Mar; 13(3):426-36. PubMed ID: 25630710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.
    Spiller HA; Mowry JB; Aleguas A; Griffith JR; Goetz R; Ryan ML; Bangh S; Klein-Schwartz W; Schaeffer S; Casavant MJ
    Ann Emerg Med; 2016 Feb; 67(2):189-95. PubMed ID: 26298448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma.
    Letertre LR; Gudmundsdottir BR; Francis CW; Gosselin RC; Skeppholm M; Malmstrom RE; Moll S; Hawes E; Francart S; Onundarson PT
    J Thromb Haemost; 2016 May; 14(5):1043-53. PubMed ID: 26924677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.
    Rousseau A; Van Dreden P; Mbemba E; Elalamy I; Larsen A; Gerotziafas GT
    Thromb Res; 2015 Dec; 136(6):1273-9. PubMed ID: 26489727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
    Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Performance Characteristics of DOAC-Remove for Neutralization of the Effects of Apixaban and Rivaroxaban in Lupus Anticoagulant Assays.
    Skaugen JM; Sayre C; Hassett AC; Chibisov I; Bontempo F; Meyer MP; Seheult JN
    Am J Clin Pathol; 2022 Mar; 157(3):457-469. PubMed ID: 34698336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro effects of Gla-domainless factor Xa analog on procoagulant and fibrinolytic pathways in apixaban-treated plasma and whole blood.
    Terada R; Johnson PM; Butt AL; Mishima Y; Stewart KE; Levy JH; Tanaka KA
    Thromb Res; 2023 Oct; 230():119-125. PubMed ID: 37713998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery.
    Schmidt K; Krüger K; Langer E; Schmutzler M; Johnen E; Wernecke KD; von Heymann C; Körber MK
    Blood Transfus; 2019 Mar; 17(2):157-162. PubMed ID: 29757137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM).
    Seyve L; Richarme C; Polack B; Marlu R
    Int J Lab Hematol; 2018 Feb; 40(1):84-93. PubMed ID: 28980758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.